Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
SWOG Cancer Research Network
Hunan Province Tumor Hospital
UNICANCER
Daiichi Sankyo
Shanghai Henlius Biotech
Gustave Roussy, Cancer Campus, Grand Paris
Trans Tasman Radiation Oncology Group
Guangdong Provincial People's Hospital
Sun Yat-sen University
Ferring Ventures Limited
Regeneron Pharmaceuticals
Hunan Province Tumor Hospital
AstraZeneca
BeiGene
Jiangsu Simcere Pharmaceutical Co., Ltd.
Fudan University
Swiss Cancer Institute
Shanghai Pulmonary Hospital, Shanghai, China
Tongji University
Rennes University Hospital
Shanghai Junshi Bioscience Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Bristol-Myers Squibb
Centre Francois Baclesse
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Alliance for Clinical Trials in Oncology
Hoffmann-La Roche
Intergroupe Francophone de Cancerologie Thoracique
National Cancer Institute (NCI)
International Atomic Energy Agency
QLT Inc.
QLT Inc.
National Cancer Center, Korea